Abliva

Abliva develops medicines for the treatment of mitochondrial disease. This congenital, rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.

Addressing Primary Mitochondrial Disease

Primary mitochondrial disease is a rare orphan disease where the energy metabolism in the cells, by the powerhouses of our cells – the mitochondria – is impaired. This causes deterioration that leads to multifaceted disorders and great suffering for patients. Mitochondrial medicine has become an area of ever-increasing focus for the pharmaceutical industry, as there are currently no effective treatment options. Through Abliva’s research and development, we have an opportunity to improve the health and quality of life of these patients.